Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Oct 1, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Avastin Biosimilar Meets Phase III Endpoints, Demonstrating Clinical Equivalence in Lung Cancer


Amgen and Allergan plc. announced positive top-line results from Avastin biosimilar candidate ABP 215, which met its primary and secondary endpoints in a phase III trial in advanced non-squamous non-small cell lung cancer.

ABP 215 is being developed as a biosimilar to Avastin, a recombinant immunoglobulin G1 monoclonal antibody that binds to vascular endothelial growth factor and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 and VEGF receptor-2.

The primary endpoint, objective response rate, was within the prespecified margin for ABP 215 compared to Avastin (bevacizumab), showing clinical equivalence.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.